C-2GPETeam Everest
TechBio AI, in-silico discovery, molecular design
discoverydiscoveringbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-2GPE
C-2GPEC-2GPETechBio AI, in-silico discovery, molecular design
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Team Everest TechBio AI, in-silico discovery, molecular design
iMetabolic Biopharma says it is using proprietary TechBio AI and its iPlatform to improve therapeutic discovery and development. Its computational approach uses in-silico therapeutic discovery and molecular design, with a focus on obesity-related comorbidities. The company lists programs for cardiovascular disease, HLP3, neurodegenerative disease, and metabolic disease.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Team Everest — Far from goals · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: exploratory. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic